The Committee on Safety of Medicines (CSM) was an independent advisory committee that advised the
UK Licensing Authority on the quality, efficacy, and safety of
medicines.
Following the
thalidomide tragedy of 1957 to 1961, in 1963 the government asked
Sir Derrick Dunlop to set up a committee to investigate the control and introduction of new medicines in the United Kingdom. In June 1963 the Committee on Safety of Drugs (CSD) was established. As a result of the subsequent report to the
Department of Health, which reinforced the need for specially trained doctors (clinical pharmacologists) in pharmaceutical companies and academic departments of medicine, Dunlop became the first chairman of the Committee. Under the
Medicines Act 1968, the CSD was replaced in 1970 by the Medicines Commission, which established the Committee on Safety of Medicines (CSM) as a Government advisory committee under Section 4 of the Act.
It was replaced on 30 October 2005 by the
Commission on Human Medicines which combines the functions of both the Committee on Safety of Medicines and the
Medicines Commission.
Chairs
* The first chairman of the CSD was Sir Derek Dunlop.
* The first chairman of the CSM was Sir Eric Scowan.
* 1980–1986. Professor Sir Abraham Goldberg
* 1987–1992. Professor Sir
William Asscher, previously chair of the
Committee on the Review of Medicines
* 1993–1998. Professor Sir Michael Rawlins
* 1999–2005. Professor Sir Alasdair Breckenridge
For later chairs, see
Commission on Human Medicines
See also
*
Medicines and Healthcare products Regulatory Agency
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care in the United Kingdom which is responsible for ensuring that medicines and medical devices work and are acceptably ...
References
{{DEFAULTSORT:Committee On Safety Of Medicines
Medical regulation in the United Kingdom
Defunct public bodies of the United Kingdom